Navigation Links
FDA, NIH to Speak at CBI's 14th Annual Registries and Post-Approval Studies Congress

WOBURN, Mass., Aug. 18, 2011 /PRNewswire/ -- CBI is pleased to announce the full agenda for its industry-leading, 14th Annual Registries and Post-Approval Studies Congress, being held September 20-22, 2011 in Philadelphia, PA. The program, sponsored by REGISTRAT-MAPI, boasts an impressive speaker lineup from Celgene, Covidien, FDA, Forest, Ironwood Pharmaceuticals, Merck, NIH, Pfizer, Takeda Europe and many more.

Attendees have the opportunity to customize their congress experience by choosing between breakout sessions, concurrent tracks and participating in interactive panel discussions. Session highlights include:

  • Driving Value in Research by Designing, Implementing and Improving Patient Registries
  • Optimizing Post-Marketing Requirements and REMS
  • Developing Strategies to Benefit Sponsor and Regulatory Authorities
  • Complying with U.S., EU and Canadian Post-Approval Requirements
  • Responding to Increased Payer Requirements to Support Reimbursement Decisions
  • Maximizing the Value of Registries and Other Post-Approval Studies

Industry leaders will be afforded the exclusive opportunity to participate in the Invitation-Only Post-Approval Executive Summit hosted by REGISTRAT-MAPI. This 5th Annual Summit provides a unique forum for senior-level executives involved in post-approval studies, including clinical, medical, safety and regulatory to address the strategic issues they face.

CBI's Post-Approval Studies series is the industry's premier source for cutting-edge content and unparalleled programming related to post-approval studies. For more information on the conference or to view the entire agenda, please visit

About CBI:

CBI, a subsidiary of Advanstar, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators. For more information, please visit

About REGISTRAT-MAPI, Global Foundation Sponsor:

REGISTRAT-MAPI provides strategic and operational solutions for our clients in the design and implementation of Late Phase studies. REGISTRAT-MAPI is the pharmaceutical industry's largest global CRO dedicated exclusively to real-world clinical research. With more than 250 experienced professionals, REGISTRAT-MAPI has served the pharmaceutical and medical device industries for more than 20 years. For more information, please visit

For additional information or media inquiries, please contact Emily Forest, CBI Marketing Manager, at 339-298-2156 or Amy Wynn, REGISTRAT-MAPI Manager, Global Marketing, at 215-568-0121.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Accuray Incorporated to Speak at 2011 Wedbush Life Sciences: Management Access Conference
2. Pathogenica CSO Speaks at IBC Life Sciences Drug Discovery & Diagnostic Development Week
3. Qteros Management to Speak at June Conferences
4. CBI Keynote Speakers on Cover of Time Magazine
5. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
6. Pam Marrone to Speak at Ag 2.0 Conference
7. Pharma ChemOutsourcing 2011 Unveils First Wave of 50 Biotech Chemist Speakers for September 12-15 Show in New Jersey
8. Science advisor to the US EPA to speak to industry, academic leaders on sustainability innovations
9. PRA International Expert to Speak at China Drug Safety Summit
10. Tianyins Dr. James Jiayuan Tong is Invited to Speak at the CFO China Summit 2011 on January 19, 2011 at the St. Regis Hotel, Beijing
11. Accuray Incorporated to Speak at Seventh Annual Lazard Capital Markets Healthcare Conference
Post Your Comments:
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology:
(Date:10/4/2017)... 4, 2017  GCE Solutions, a global clinical research organization (CRO), ... anonymization solution on October 4, 2017. Shadow is designed to assist ... with policy 0070 of the European Medicines Agency (EMA) in meeting ... ... ...
(Date:8/15/2017)... --  ivWatch LLC , a medical device company focused on improving ... of its ISO 13485 Certification, the global standard for medical device ... (ISO®). ... Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
Breaking Biology News(10 mins):